Please login to the form below

Not currently logged in

Christian Schade joins Aprea AB

He takes up the role of president and chief executive officer

Aprea Christian SchadeSwedish biopharmaceutical firm Aprea AB has appointed Christian Schade as its president and chief executive officer.

Schade joins Aprea's Boston, Massachusetts office, bringing over 30 years of pharma and biotech industry experience, as well as corporate finance expertise, to his new role.

Most recently, Schade served as chief executive officer of Novira Therapeutics, which was acquired by Johnson & Johnson at the end of last year.

Prior to this, he worked at Omthera, a specialty dyslipidemia-focused pharmaceutical company, as executive vice president and chief financial officer during which time, Schade oversaw Omthera's sale to AstraZeneca.

Schade has also served as executive vice president and chief financial officer at Energy, and was senior vice president of administration and chief financial officer at Medarex where he led negotiations for the company's acquisition by Bristol-Myers Squibb.

Bernd Seizinger, chairman of Aprea's board of directors, said: “I am delighted to welcome Chris to Aprea.

“He is an accomplished biopharmaceutical executive with proven experience leading companies through times of change and growth.

“He will be an important asset to Aprea as we continue to develop novel anticancer therapies targeting the tumour suppressor protein, p53.

“Furthermore, Chris has excellent credentials to build a strategic leadership team in the US to complement the R&D activities of the team in Sweden.”

24th June 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?